



HAL
open science

Total synthesis of the four stereoisomers of cyclo(L-Trp-L-Arg) raises uncertainty of the structures of the natural products and invalidates their promising antimicrobial activities

Dan Chen, Daniel Park, Melissa Cadelis, Hana Douafer, Marie-Lise Bourguet-Kondracki, Jean Michel Brunel, Brent Copp

► To cite this version:

Dan Chen, Daniel Park, Melissa Cadelis, Hana Douafer, Marie-Lise Bourguet-Kondracki, et al.. Total synthesis of the four stereoisomers of cyclo(L-Trp-L-Arg) raises uncertainty of the structures of the natural products and invalidates their promising antimicrobial activities. *Molecules*, 2022, 27 (18), pp.5913. 10.3390/xxxxx . hal-03807564

HAL Id: hal-03807564

<https://hal.science/hal-03807564v1>

Submitted on 10 Oct 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

1 Article

2 Total synthesis of the four stereoisomers of cyclo(L-Trp-L-Arg) 3 raises uncertainty of the structures of the natural products and 4 invalidates their promising antimicrobial activities

5 Dan Chen ¹, Daniel J. Park ¹, Melissa M. Cadelis ¹, Hana Douafer ², Marie Lise Bourguet-Kondracki ³, Jean Michel
6 Brunel ², and Brent R. Copp ^{1,*}

7 ¹ School of Chemical Sciences, The University of Auckland, Waipapa Taumata Rau, Private Bag 92019, Auck-
8 land 1142, New Zealand; dche806@aucklanduni.ac.nz (D.C.); m.cadelis@auckland.ac.nz (M.M.C.);
9 jpar352@aucklanduni.ac.nz (D.J.P.); b.copp@auckland.ac.nz (B.C)

10 ² Aix-Marseille Universite, INSERM, SSA, MCT, Faculté de Pharmacie, 27 bd Jean Moulin, 13385 Marseille,
11 France; hana.douafer@hotmail.com (H.D.); jean-michel.brunel@inserm.fr (J.M.B.)

12 ³ Laboratoire Molécules de Communication et Adaptation des Micro-organismes, UMR 7245 CNRS, Muséum
13 National d'Histoire Naturelle, 57 rue Cuvier (C.P. 54), 75005 Paris, France; marie-lise.bourguet@mnhn.fr
14 (M-L.B-K)

15 * Correspondence: b.copp@auckland.ac.nz

Citation: Chen, D.; Park, D.J.;

Cadelis, M.M.; Douafer, H.; 16

Bourguet-Kondracki, M.L.; Brunel, 17

J.M.; Copp, B.R. Total synthesis of 18

the four stereoisomers of 19

cyclo(L-Trp-L-Arg) raises uncertainty 20

of the structures of the natural 21

products and invalidates their 22

promising antimicrobial activities. 23

Molecules **2022**, *27*, x. 24

<https://doi.org/10.3390/xxxxx> 25

Academic Editor: Firstname 26

Lastname 27

Received: date 28

Accepted: date 29

Published: date 30

Publisher's Note: MDPI stays 31

neutral with regard to jurisdictional 32

claims in published maps and 33

institutional affiliations. 34

35

36

37

38

39

40

41

42

43

44

Abstract: New therapeutic options to combat the growing incidence of antimicrobial resistance are urgently needed. A 2015 publication reported the isolation and biological evaluation of two diketopiperazine natural products cyclo(L-Trp-L-Arg) (CDP 2) and cyclo(D-Trp-D-Arg) (CDP 3) from an *Achromobacter* sp. bacterium, finding that the latter metabolite in particular exhibited strong antibacterial activity towards a range of wound-related microorganisms and could synergise the action of ampicillin. Intrigued by these biological activities and noting inconsistencies in the structural characterization of the natural products we have synthesized the four diastereomers of cyclo(Trp-Arg) and evaluated them for antimicrobial and antibiotic enhancement properties. Detailed comparison of spectroscopic data raises uncertainty regarding the structure of CDP 2 and disproves the structure of CDP 3. In our hands, none of the four stereoisomers of cyclo(Trp-Arg) exhibited detectable intrinsic antimicrobial properties towards a range of Gram-positive and Gram-negative bacteria or fungi nor could they potentiate the action of antibiotics. These discrepancies in biological properties, compared to the activities reported in the literature, reveal that these specific cyclic dipeptides do not represent viable templates for the development of new treatments for microbial infections.

Keywords: diketopiperazine; cyclo(Trp-Arg); natural product; synthesis; structure revision; anti-microbial; antibiotic enhancement;



Copyright: © 2022 by the authors. 34

Submitted for possible open access 35

publication under the terms and 36

conditions of the Creative Commons 37

Attribution (CC BY) license 38

(<https://creativecommons.org/licenses/by/4.0/>) 39

40

1. Introduction

The identification of new antimicrobials is becoming more urgent with the growing incidence and prevalence of antimicrobial resistance [1]. While natural products represented some of the most central examples of antibiotics in the so-called “Golden Age” of antibiotics, interest in their discovery and development by major pharmaceutical companies fell to the wayside in the 1980’s [2]. The overall lack of success that followed the subsequent focus on combinatorial chemistry driven by target-specific screening has led to a revival of phenotypic-based screening that encompasses investigation of libraries that include natural products [3–5].

In continuation of our ongoing interest in the discovery and development of new antimicrobials and antibiotic enhancers,[6,7] we were interested in a publication report-

ing the structures of three diketopiperazines from the bacterium *Achromobacter* sp. [8], two of which were claimed to be the enantiomers cyclo(L-trp-L-Arg) (CDP 2, **1**) and cyclo(D-trp-D-Arg) (CDP 3, **2**) (**Figure 1**). While the former natural product was only mildly active, the latter exhibited pronounced growth inhibition of a range of Gram-positive and Gram-negative bacteria with MIC 0.5–64 µg/mL. Especially of interest to us was the observation of synergism for either compound in combination with ampicillin towards a range of wound associated bacteria. Of note was the exceptionally low checkerboard assay FICI value (0.09) for the ampicillin + **2** combination towards the Gram-negative bacterium *Pseudomonas aeruginosa*. Overall, these results suggested that compounds **1** and **2** could represent a template from which to develop new examples of antimicrobial and antibiotic enhancing compounds.




Figure 1. Proposed structures of CDP 2 (**1**) and CDP 3 (**2**) [8].

Before commencing an expansive structure-activity relationship study, a closer inspection of the structure elucidation and characterization of natural products **1** and **2** raised some inconsistencies:

1. While **1** and **2** were reported to be enantiomers, supported by the observation of similar magnitude and opposite sign specific rotations of +145 and -167, and essentially identical melting points ranges of 265.1–267.34 °C and 262.23–265.58 °C, respectively, they were reported to have different ¹H and ¹³C NMR chemical shifts in the same (achiral) solvent (DMSO-*d*₆).
2. Although analyzed for purity using an achiral C18 column HPLC system, compounds **1** and **2** exhibited different retention times of 20.241 min and 11.232 min, respectively.
3. Stereochemistry was attributed using standard Marfey's analysis, but no HPLC traces were presented – the results were 'data not shown'.
4. Molecular formulae (C₁₇H₂₃N₆O₂) for **1** and **2** were assigned by analysis of HRESIMS [M+H]⁺ data, but the reported observed values of *m/z* 343.39558 and 343.37431 were significantly different from the expected exact mass of *m/z* 343.18770 (Bruker Compass DataAnalysis v 4.1) (with mass errors of 606 ppm and 544 ppm, respectively being far in excess of the acceptable 4–5 ppm error range) and are in fact closer to the average mass value of 343.41405.
5. The experimental section states that the natural products were purified using silica gel column chromatography eluting with dichloromethane-hexane and ethyl acetate-dichloromethane solvent mixtures, followed by crystallization using hexane and benzene. These conditions are particularly suited to the purification of non-polar natural products, however given the basic nature of the guanidine group (pK_a ~ 12.5), these natural products would have been isolated as salts (of undefined counterion) and would not have eluted from a silica column under the stated conditions.


These inconsistencies raised questions as to the proposed structures of the bacterial-derived diketopiperazine natural products cyclo(L-Trp-L-Arg) **1** and cyclo(D-Trp-D-Arg) **2**. Therefore, we undertook the total synthesis and characterization of the four stereoisomers of cyclo(Trp-Arg) and evaluation of their antimicrobial and anti-

biotic enhancing properties. Herein, we report the results of these studies that have led us to question the structure of CDP2 and disprove the structure of CDP3. A lack of detectable biological activity of the four synthetic stereoisomers reveals that these molecules have no potential to act as templates for new antibiotics or adjuvants.

2. Results and Discussion

The synthesis of all four stereoisomers of cyclo(Trp-Arg) has been previously reported, without experimental details [9,10], and comprehensively characterized using NMR and combinations of vibrational and electronic circular dichroism. Unfortunately, the NMR solvents and chiroptical techniques used by those authors were different to those used to characterize natural products **1** and **2** preventing direct comparison.

We chose to synthesize the four stereoisomers of cyclo(Trp-Arg) using the general procedure shown in Scheme 1. Coupling of Trp-OMe with *N* α -Boc-Arg mediated by (2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) / hydroxybenzotriazole (HOBT) afforded protected dipeptide **3a-d** (yields of 56–91%), which were then subjected to reaction with trifluoroacetic acid in dichloromethane to give dipeptide methylester **4a-d** as the di-TFA salt. Incubation of **4a-d** with NH₄OH in MeOH [11] at room temperature for 24h gave, after purification using C8 reversed-phase column chromatography, the target cyclo(Trp-Arg) diketopiperazines **5a-d** as the presumed mono TFA salt. Little to no evidence was observed for the formation of racemization products during the mild conditions used for the diketopiperazine ring closure.



Scheme 1. General synthetic route for the synthesis of cyclo(Trp-Arg) stereoisomers.

Reagents and conditions: (a) TFA (0.2 mL) in CH₂Cl₂ (2 mL), N₂, 2h (55–69%); (b) NH₄OH in MeOH, rt, 24h (47–71%).

Each of the diastereomers **5a-d** were characterized by ESI mass spectrometry, chiroptically and by NMR, with complete 1-D and 2-D data sets acquired separately in DMSO-*d*₆ and CD₃OD (see Supporting Information Figures S1 – S8 for ¹H and ¹³C spectra). As anticipated, all four stereoisomers exhibited essentially the same ESIMS protonated molecular ion ([M+H]⁺ *m/z* 343.1870±0.0003 (0.9–2.9 ppm error), which exact mass matched to the anticipated molecular formula (see Experimental). Chiroptical characterization of the four diastereomers used a combination of specific rotation and electronic circular dichroism (ECD). Enantiomer pairs **5a,b** and **5c,d** exhibited equal magnitude and opposite sign using both techniques, while diastereomeric pairs (**5a,c** and **5b,d**) were noticeable different (specific rotation values given in Table 1, ECD spectra shown in Figure 2).

Table 1. Specific rotation values observed for diketopiperazines **5a-d**.

Cmpd	$[\alpha]_D^1$	Lit.
5a cyclo(L-Trp-L-Arg)	-10.5 (<i>c</i> 0.105, MeOH)	-13 [14]
5b cyclo(D-Trp-D-Arg)	+10.7 (<i>c</i> 0.103, MeOH)	
5c cyclo(L-Trp-D-Arg)	+26.0 (<i>c</i> 0.131, MeOH)	
5d cyclo(D-Trp-L-Arg)	-26.4 (<i>c</i> 0.421, MeOH)	

¹ Acquired in MeOH at the concentration given in g/100 mL.

Our results were consistent with two previous studies of cyclo(Trp-Arg), with $[\alpha]_D$ for **5a** being close to the value reported by Sasaki *et al.* for cyclo(L-Trp-L-Arg) (lit. [12] -13 (H₂O) vs **5a** $[\alpha]_D$ (MeOH) -10.5), and with the ECD Cotton effects and $\Delta\epsilon$ values in close agreement with those reported for cyclo(L-Trp-L-Arg) and cyclo(L-Trp-D-Arg) by Li *et al.* [9].




Figure 2. Electronic circular dichroism spectra observed for diketopiperazines **5a** and **5b** (left) and **5c** and **5d** (right).

Enantiomeric pairs of the diketopiperazines also exhibited identical ¹H and ¹³C NMR spectra while subtle differences were observed between diastereomers. As described at length by Li *et al.*, *syn* diastereomers of cyclo(Trp-Arg) **5a** and **5b** i.e. those with the tryptophan and arginine sidechains on the same face of the diketopiperazine ring, exhibit diagnostically shielded chemical shifts for arginine sidechain protons H₂-7 and H₂-8 (δ_H 0.87–0.49) versus the corresponding *anti* diastereomers **5c** and **5d** (H₂-7 and H₂-8, δ_H 1.67–1.44). Careful comparison of our data with those previously reported by Li *et al.* [12] showed good to excellent agreement (as measured by mean absolute error (MAE) values) with ¹H and ¹³C chemical shifts (CD₃OD, plus ¹H exchangeables observed in DMSO-*d*₆) for **5a,b** (¹H MAE 0.014; ¹³C MAE 0.02) and **5c,d** (¹H MAE 0.005; ¹³C MAE 0.00) (Tables S1 and S2).

Safe in the knowledge that our spectroscopic data observed for **5a-d** were in agreement with previously reported data for the same compounds, we then compared our data with those reported by Deepa *et al.* for **1** and **2**. This analysis is summarized as follows:

- ¹H NMR. The ¹H chemical shifts reported for H₂-7 and H₂-8 of the natural products **1** and **2** were in the shielded region with δ_H 0.81–0.54 (**1**) and δ_H 0.88–0.61 (**2**), consistent with both having *syn* substitution on the diketopiperazine ring as claimed. While stated to have been recorded in DMSO-*d*₆ solvent, neither set of ¹H NMR data reported for **1** and **2** agreed with our data acquired for LL/DD (**5a,b**) in DMSO-*d*₆ (**1** vs

160 **5a,b** MAE 0.12, **2** vs **5a,b** MAE 0.17) (Tables S3 and S4). A better match (based upon
161 lowest MAE) was found for **1** when compared to data acquired in CD₃OD solvent
162 with the addition of ¹H exchangeable shifts reported from DMSO-*d*₆ data (**1** vs **5a,b**
163 MAE 0.05, **2** vs **5a,b** MAE 0.11) (Tables S3 and S4). Thus, we concluded that **1** was
164 indeed a diketopiperazine bearing *syn* disubstitution but that the NMR data had ac-
165 tually been acquired in CD₃OD with exchangeable ¹H chemical shifts determined in
166 DMSO-*d*₆ solvent.

- 167 2. ¹³C NMR. Similar comparison of ¹³C NMR data reported for **1** and **2** with the chemical
168 shifts acquired for **5a,b** in either CD₃OD or DMSO-*d*₆ identified the closest fit to be for
169 natural product CDP 2 **1** and our CD₃OD solvent data set (MAE 0.1) (Tables S5 and
170 S6).

171 Based upon our analysis of ¹H and ¹³C NMR data, we could conclude that natural
172 product **1** was indeed a *syn* substituted diketopiperazine (as claimed) [8] but that the
173 original NMR data was acquired in CD₃OD and using DMSO-*d*₆ solvent to observe
174 the exchangeable NH proton signals. Given enantiomers exhibit identical NMR data
175 (when acquired in achiral solvents), we are not able to assign a structure or relative
176 configuration to natural product CDP3 **2** at this time.

- 177 3. Specific rotation. With the preceding analysis of NMR data suggesting natural
178 product **1** was indeed a *syn* substituted diketopiperazine, we next used comparison
179 of specific rotation values to assign absolute configuration. A large magnitude dex-
180 trorotatory value was reported for **1** ([α]_D (c 0.02, MeOH) +145 while we observed
181 low magnitude values of -10.5 (for **5a**) and +10.7 (for **5b**). A previously reported spe-
182 cific rotation for cyclo(L-Trp-L-Arg) (hydrochloride salt) of -13 (H₂O) [12] is in good
183 agreement with our data [12]. These results revealed a disconnect between the spe-
184 cific rotation and peptide hydrolysis results reported for CDP 2 [8] and our data but,
185 as we don't have access to authentic samples of the natural products, we are unable
186 to determine which information reported for the natural product is incorrect. We
187 conclude that there remains uncertainty regarding the absolute configuration of CDP
188 **2**.

189 In their natural product isolation paper, Deepa *et al.* reported that diketopiperazines **1**
190 and **2** exhibited modest to moderate levels of activity towards a panel of
191 wound-associated bacterial pathogens including *Staphylococcus aureus* (**1**, MIC 64 µg/mL;
192 **2**, 0.5 µg/mL), *P. aeruginosa* (**1**, MIC 250 µg/mL; **2**, 0.5 µg/mL) and *Klebsiella pneumoniae* (**1**,
193 MIC 125 µg/mL; **2**, 2 µg/mL) [8]. The intrinsic antimicrobial activity of **5a-d** was evaluated
194 against a range of Gram-positive (*S. aureus* and MRSA) and Gram-negative (*Escherichia*
195 *coli*, *P. aeruginosa*, *K. pneumoniae* and *Acinetobacter baumannii*) bacteria and two fungal
196 strains (*Candida albicans* and *Cryptococcus neoformans*). Cytotoxicity towards HEK293
197 (human kidney epithelial cell line and hemolytic activity against human red blood cells
198 were also determined. In all cases, our synthetic samples **5a-d** were found to be biologi-
199 cally inactive, with no detectable growth inhibition at the highest test concentrations of
200 350 µg/mL (for *S. aureus*, *E. coli* and *P. aeruginosa*) and 32 µg/mL (for all other assays) (data
201 not shown).

202 While the structure assignment was confirmed, the synthetically-derived materials did
203 not possess any antibacterial activity nor any doxycycline or ampicillin enhancing prop-
204 erties towards *P. aeruginosa* PAO1 when tested at a range of concentrations up to 400 µM
205 as previously reported for the natural products [8]. Unfortunately, the originally isolated
206 natural product material was not available for direct comparison with the synthetic
207 compounds. Our results reveal that these diketopiperazine derivatives are not antibacte-
208 rial agents or antibiotic enhancers.

3. Materials and Methods

3.1. Chemical Synthesis General Methods

Mass spectra were recorded using a MicroTOF-QII mass spectrometer (Bruker Daltonics, Bremen, Germany) coupled with a KD Scientific syringe pump, with analysis using Bruker Compass DataAnalysis v 4.1 software. Infrared spectra were recorded on a Perkin Elmer Spectrum 100 Fourier Transform infrared spectrometer equipped with a universal ATR accessory. Optical rotations were obtained with a Rudolph Analytical Autopol IV automatic polarimeter using a 0.1 dm cell (concentration units of g/100 mL). Electronic circular dichroism readings were obtained with a Chirascan circular dichroism spectrometer using a 1 mm cuvette (concentration units of mol/L). All NMR spectra were recorded using a Bruker Avance 400 spectrometer operating at 400.13 for ^1H nuclei and 100.62 for ^{13}C nuclei. Chemical shifts are expressed in parts per million (ppm) relative to the solvent peaks (DMSO- d_6 : ^1H 2.50, ^{13}C 39.52 ppm; CD $_3$ OD: ^1H 3.31, ^{13}C 49.00 ppm). Assignments are based on 1- and 2-dimensional NMR experiments and analogue comparisons. Standard Bruker pulse sequences were utilized. Reversed-phase flash column chromatography was carried out using LiChroPrep RP-8 (40–63 μm) (Merck). Analytical thin layer chromatography (TLC) was carried out on 0.2 mm thick plates of Merck DC Kieselgel 60 RP-18 F254S plates. All solvents were of analytical grade or better and/or purified according to standard procedures. Chemical reagents used were purchased from standard chemical suppliers and used as purchased.

3.1.1. General procedure A: amide bond formation.

To a stirred solution of *N* α -Boc-Arg-OH hydrochloride (1.05 eq), Trp-OMe (1.0 eq.), HOBt (3.6 eq.) and diisopropylethylamine (DIPEA) (4.8 eq.) in anhydrous DMF (2 mL) at 0°C was added HBTU (1.2 eq.). The reaction mixture was stirred for 1.5 h under N $_2$ atmosphere and then ethyl acetate (50 mL) was added and the organic layer was washed with citric acid (100 mL), sat. NaHCO $_3$ (100 mL) and brine (100 mL), then dried with anhydrous MgSO $_4$. The organic layer was then dried in vacuo before being taken to the next step without further purification.

3.1.2. General procedure B: Boc deprotection.

A solution of the *tert*-butyl-carbamate derivative was stirred in CH $_2$ Cl $_2$ (2 mL) with TFA (0.2 mL) at room temperature under N $_2$ for 2 h, then dried in vacuo. The crude product was purified using C $_8$ reversed-phase column chromatography (MeOH (+0.05% TFA):H $_2$ O (+0.05 % TFA), 0:100 \rightarrow 1:3) to afford the product as the di-TFA salt.

3.1.3. General procedure C: Diketopiperazine formation.

To a solution of deprotected dipeptide in MeOH (0.25 M) at 0°C was added NH $_4$ OH (28–30% in H $_2$ O, 1 mL per 6 mL MeOH) dropwise. The reaction mixture was stirred for 24 h after which the crude product was purified using C $_8$ reversed-phase column chromatography eluting with water.

3.1.4. Methyl (*tert*-butoxycarbonyl)-L-arginyl-L-tryptophanate hydrochloride (3a).

Following general procedure A, reaction of *N* α -Boc-L-Arg-OH (56 mg, 0.206 mmol), L-tryptophan methyl ester hydrochloride (50 mg, 0.196 mmol), HOBt (96 mg, 0.706 mmol), DIPEA (0.16 mL, 0.941 mmol) and HBTU (89 mg, 0.235 mmol) afforded the hydrochloride salt of dipeptide **3a** as a clear oil/gum (91 mg, 91%). $[\alpha]^{25}_D$ +0.77 (*c* 0.130, MeOH); R_f = 0.09 (MeOH); IR (ATR) ν_{max} 3362, 2952, 2844, 1738, 1659, 1524, 1162, 1016, 824 cm $^{-1}$; ^1H NMR (400 MHz, DMSO- d_6) δ 10.92–10.87 (1H, m, NH-5), 8.20 (1H, d, *J* = 7.2 Hz, NH-11), 7.72–7.62 (1H, m, NH-17), 7.48 (1H, d, *J* = 7.5 Hz, H-9), 7.34 (1H, d, *J* = 7.5 Hz, H-6), 7.18–7.14 (1H, m, H-4), 7.09–7.03 (1H, m, H-7), 7.01–6.95 (1H, m, H-8), 6.88 (1H, d, *J*

= 8.1 Hz, NH-21), 4.53 (1H, dt, $J = 6.8, 6.8$ Hz, H-1), 4.02–3.94 (1H, m, H-13), 3.54 (3H, br s, OMe), 3.15–3.10 (1H, m, H-2a), 3.10–3.06 (1H, m, H-2b), 3.08–3.02 (2H, m, H₂-16), 1.67–1.55 (1H, m, H-14a), 1.53–1.41 (3H, m, H-14b, H₂-15), 1.37 (9H, br s, Boc); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 172.1 (C-10/C-12), 172.0 (C-10/C-12), 156.7 (C-18), 155.2 (Boc), 136.1 (C-5a), 127.0 (C-9a), 123.7 (C-4), 121.0 (C-7), 118.4 (C-8), 117.9 (C-9), 111.4 (C-6), 109.1 (C-3), 78.2 (Boc), 53.6 (C-13), 53.0 (C-1), 51.8 (OMe), 40.4 (C-16), 29.1 (C-14), 28.2 (Boc), 27.0 (C-2), 25.0 (C-15); (+)-HRESIMS [M+H]⁺ m/z 475.2647 (calcd for C₂₃H₃₅N₆O₅, 475.2663).

3.1.5. Methyl (*tert*-butoxycarbonyl)-D-arginyl-D-tryptophanate hydrochloride (**3b**).

Following general procedure A, reaction of *N* α -Boc-D-Arg-OH hydrochloride (64 mg, 0.206 mmol), D-Trp-OMe hydrochloride (50 mg, 0.196 mmol), HOBt (95 mg, 0.706 mmol), DIPEA (0.16 mL, 0.941 mmol) and HBTU (89 mg, 0.235 mmol) afforded the hydrochloride salt of dipeptide **3b** as a clear oil/gum (56 mg, 56%). [α]²¹_D -0.74 (*c* 0.136, MeOH); $R_f = 0.09$ (MeOH); IR (ATR) ν_{\max} 3364, 2953, 2837, 1738, 1658, 1520, 1161, 839 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.92–10.82 (1H, m, NH-5), 8.20 (1H, d, $J = 7.0$ Hz, NH-11), 7.49 (1H, d, $J = 8.1$ Hz, H-9), 7.35 (1H, d, $J = 8.1$ Hz, H-6), 7.20–7.16 (1H, m, H-4), 7.11–7.05 (1H, m, H-7), 7.03–6.97 (1H, m, H-8), 6.88 (1H, d, $J = 8.1$ Hz, NH-21), 4.59–4.50 (1H, m, H-1), 4.05–3.96 (1H, m, H-13), 3.56 (3H, br s, OMe), 3.16–3.11 (1H, m, H-2a), 3.11–3.04 (3H, m, H-2b, H₂-16), 1.68–1.57 (1H, m, H-14a), 1.55–1.42 (3H, m, H-14b, H₂-15), 1.39 (9H, br s, Boc); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 172.1 (C-10/C-12), 172.0 (C-10/C-12), 156.7 (C-18), 155.2 (Boc), 136.1 (C-5a), 127.0 (C-9a), 123.7 (C-4), 121.0 (C-7), 118.4 (C-8), 117.9 (C-9), 111.4 (C-6), 109.1 (C-3), 78.2 (Boc), 53.6 (C-13), 53.0 (C-1), 51.8 (OMe), 40.4 (C-16), 29.1 (C-14), 28.2 (Boc), 27.0 (C-2), 25.0 (C-15); (+)-HRESIMS [M+H]⁺ m/z 475.2650 (calcd for C₂₃H₃₅N₆O₅, 475.2663).

3.1.6. Methyl (*tert*-butoxycarbonyl)-D-arginyl-L-tryptophanate hydrochloride (**3c**).

Following general procedure A, reaction of *N* α -Boc-D-Arg-OH hydrochloride (64 mg, 0.206 mmol), L-Trp-OMe hydrochloride (50 mg, 0.196 mmol), HOBt (95 mg, 0.706 mmol), DIPEA (0.16 mL, 0.941 mmol) and HBTU (89 mg, 0.235 mmol) afforded the hydrochloride salt of dipeptide **3c** as a clear oil/gum (67 mg, 67%). [α]²¹_D +0.98 (*c* 0.102, MeOH); $R_f = 0.09$ (MeOH); IR (ATR) ν_{\max} 3357, 2954, 1731, 1653, 1516, 1368, 1161, 837 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.86 (1H, d, $J = 2.0$ Hz, NH-5), 8.17 (1H, d, $J = 7.9$ Hz, NH-11), 7.48 (1H, d, $J = 7.9$ Hz, H-9), 7.40 (1H, t, $J = 5.2$ Hz, NH-17), 7.34 (1H, d, $J = 7.9$ Hz, H-6), 7.12 (1H, d, $J = 2.0$ Hz, H-4), 7.07 (1H, ddd, $J = 8.2, 7.9, 1.0$ Hz, H-7), 6.99 (1H, ddd, $J = 8.2, 7.9, 1.0$ Hz, H-8), 6.84 (1H, d, $J = 8.2$ Hz, NH-21), 4.51 (1H, dt, $J = 8.6, 6.2$ Hz, H-1), 3.97 (1H, dt, $J = 9.2, 5.9$ Hz, H-13), 3.58 (3H, br s, OMe), 3.20–3.11 (1H, m, H-2a), 3.10–3.04 (1H, m, H-2b), 3.02–2.96 (2H, m, H₂-16), 1.58–1.47 (1H, m, H-14a), 1.47–1.37 (1H, m, H-14b), 1.38 (9H, br s, Boc), 1.37–1.28 (2H, m, H₂-15); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 172.1 (C-10/C-12), 171.8 (C-10/C-12), 156.6 (C-18/Boc), 155.2 (C-18/Boc), 136.1 (C-5a), 127.0 (C-9a), 123.7 (C-4), 121.0 (C-7), 118.4 (C-8), 117.9 (C-9), 111.4 (C-6), 109.2 (C-3), 78.2 (Boc), 53.6 (C-13), 52.9 (C-1), 51.8 (OMe), 40.4 (C-16), 29.1 (C-14), 28.2 (Boc), 27.2 (C-2), 24.9 (C-15); (+)-HRESIMS [M+H]⁺ m/z 475.2651 (calcd for C₂₃H₃₅N₆O₅, 475.2663).

3.1.7. Methyl (*tert*-butoxycarbonyl)-L-arginyl-D-tryptophanate hydrochloride (**3d**).

Following general procedure A, reaction of *N* α -Boc-L-Arg-OH (113 mg, 0.413 mmol), D-Trp-OMe hydrochloride (100 mg, 0.393 mmol), HOBt (190 mg, 1.41 mmol), DIPEA (0.33 mL, 1.89 mmol) and HBTU (179 mg, 0.472 mmol) afforded the hydrochloride salt of dipeptide **3d** as a clear oil/gum (164 mg, 82%). [α]¹⁹_D +3.0 (*c* 0.10, MeOH); $R_f = 0.11$ (MeOH); IR (ATR) ν_{\max} 3363, 2952, 2834, 1738, 1654, 1520, 1440, 1392, 1017, 841 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.88 (1H, d, $J = 1.9$ Hz, NH-5), 8.18 (1H, d, $J = 7.9$ Hz, NH-11), 7.48 (1H, d, $J = 7.5$ Hz, H-9), 7.48–7.42 (1H, m, NH-17), 7.34 (1H, d, $J = 7.5$ Hz, H-6), 7.12 (1H, d, $J = 1.9$ Hz, H-4), 7.07 (1H, ddd, $J = 8.4, 7.5, 1.2$ Hz, H-7), 6.99 (1H, ddd, $J = 8.4, 7.5, 1.2$ Hz, H-8), 6.83 (1H, d, $J = 8.3$ Hz, NH-21), 4.51 (1H, dt, $J = 7.5, 6.4$ Hz, H-1), 3.98

(1H, dt, $J = 6.2, 5.3$ Hz, H-13), 3.58 (3H, br s, OMe), 3.19–3.12 (1H, m, H-2a), 3.10–3.03 (1H, m, H-2b), 3.03–2.97 (2H, m, H₂-16), 1.58–1.46 (1H, m, H-14a), 1.46–1.36 (1H, m, H-14b), 1.40–1.28 (2H, m, H₂-15), 1.38 (9H, br s, Boc); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 172.1 (C-10/C-12), 171.8 (C-10/C-12), 156.6 (C-18), 155.2 (Boc), 136.1 (C-5a), 127.0 (C-9a), 123.7 (C-4), 121.0 (C-7), 118.4 (C-8), 117.9 (C-9), 111.4 (C-6), 109.2 (C-3), 78.2 (Boc), 53.6 (C-13), 52.9 (C-1), 51.8 (OMe), 40.4 (C-16), 28.3 (C-14, Boc), 27.2 (C-2), 24.9 (C-15); (+)-HRESIMS [M+H]⁺ m/z 475.2652 (calcd for C₂₃H₃₅N₆O₅, 475.2663).

3.1.8. Methyl L-arginyl-L-tryptophanate bis(2,2,2-trifluoroacetate) (4a).

Following general procedure B, dipeptide **3a** (49 mg, 0.096 mmol) was reacted with TFA (0.2 mL) in CH₂Cl₂ (2 mL) to afford the di-TFA salt of dipeptide **4a** a pale yellow oil/gum (33 mg, 57%). $[\alpha]^{25}_D +1.5$ (c 0.135, MeOH); $R_f = 0.35$ (MeOH); IR (ATR) ν_{max} 3350, 3199, 3067, 2958, 2879, 1667, 1630, 1532, 1200, 1135 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.95 (1H, d, $J = 2.4$ Hz, NH-5), 8.95 (1H, d, $J = 7.4$ Hz, NH-11), 8.20 (3H, d, $J = 4.0$ Hz, NH₃-21), 7.85 (1H, t, $J = 5.8$ Hz, NH-17), 7.50 (1H, d, $J = 8.0$ Hz, H-9), 7.36 (1H, d, $J = 8.0$ Hz, H-6), 7.20 (1H, d, $J = 2.4$ Hz, H-4), 7.08 (1H, ddd, $J = 8.5, 8.0, 1.0$ Hz, H-7), 7.00 (1H, ddd, $J = 8.5, 8.0, 1.0$ Hz, H-8), 4.61 (1H, dt, $J = 8.8, 6.5$ Hz, H-1), 3.89–3.80 (1H, m, H-13), 3.60 (3H, br s, OMe), 3.24–3.17 (1H, m, H-2a), 3.16–3.07 (3H, m, H-2b, H₂-16), 1.78–1.69 (2H, m, H₂-14), 1.59–1.48 (2H, m, H₂-15); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 171.8 (C-10), 168.8 (C-12), 156.9 (C-18), 136.2 (C-5a), 127.0 (C-9a), 124.0 (C-4), 121.1 (C-7), 118.6 (C-8), 117.9 (C-9), 111.6 (C-6), 108.9 (C-3), 53.4 (C-1), 52.0 (OMe), 51.7 (C-13), 40.3 (C-16), 28.5 (C-14), 27.0 (C-2), 24.0 (C-15); (+)-HRESIMS [M+H]⁺ m/z 375.2124 (calcd for C₁₈H₂₇N₆O₃, 375.2139).

3.1.9. Methyl D-arginyl-D-tryptophanate bis(2,2,2-trifluoroacetate) (4b).

Following general procedure B, Boc-protected dipeptide **3b** (52 mg, 0.110 mmol) was reacted with TFA (0.2 mL) in CH₂Cl₂ (2 mL) to afford the di-TFA salt of dipeptide **4b** as a pale yellow oil/gum (42 mg, 69%). $[\alpha]^{19}_D -1.2$ (c 0.424, MeOH); $R_f = 0.35$ (MeOH); IR (ATR) ν_{max} 3358, 3200, 3072, 2956, 2879, 1671, 1638, 1545, 1202, 1136 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.94 (1H, d, $J = 2.4$ Hz, NH-5), 8.93 (1H, d, $J = 7.1$ Hz, NH-11), 8.18 (3H, d, $J = 5.0$ Hz, NH₃-21), 7.80–7.74 (1H, m, NH-17), 7.49 (1H, d, $J = 8.0$ Hz, H-9), 7.36 (1H, d, $J = 8.0$ Hz, H-6), 7.20 (1H, d, $J = 2.4$ Hz, H-4), 7.11–7.05 (1H, m, H-7), 7.03–6.98 (1H, m, H-8), 4.64–4.57 (1H, m, H-1), 3.87–3.78 (1H, m, H-13), 3.60 (3H, br s, OMe), 3.23–3.16 (1H, m, H-2a), 3.15–3.07 (3H, m, H-2b, H₂-16), 1.77–1.67 (2H, m, H₂-14), 1.58–1.48 (2H, m, H₂-15); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 171.7 (C-10), 168.7 (C-12), 156.8 (C-18), 136.2 (C-5a), 126.9 (C-9a), 123.9 (C-4), 121.1 (C-7), 118.5 (C-8), 117.9 (C-9), 111.5 (C-6), 108.8 (C-3), 53.3 (C-1), 52.0 (OMe), 51.6 (C-13), 40.2 (C-16), 28.4 (C-14), 27.0 (C-2), 23.9 (C-15); (+)-HRESIMS [M+H]⁺ m/z 375.2133 (calcd for C₁₈H₂₇N₆O₃, 375.2139).

3.1.10. Methyl D-arginyl-L-tryptophanate bis(2,2,2-trifluoroacetate) (4c).

Following general procedure B, Boc-protected dipeptide **3c** (48 mg, 0.094 mmol) was reacted with TFA in CH₂Cl₂ to afford the di-TFA salt of dipeptide **4c** as a pale yellow oil/gum (31 mg, 55%). $[\alpha]^{25}_D -11.2$ (c 0.143, MeOH); $R_f = 0.09$ (MeOH); IR (ATR) ν_{max} 3350, 3197, 3077, 2961, 1663, 1624, 1556, 1435, 1356, 1182, 1131 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.90–10.86 (1H, m, NH-5), 8.95 (1H, d, $J = 8.0$ Hz, NH-11), 8.20–8.11 (3H, m, NH₃-21), 7.78–7.71 (1H, m, NH-17), 7.50 (1H, d, $J = 7.8$ Hz, H-9), 7.35 (1H, d, $J = 7.8$ Hz, H-6), 7.17–7.15 (1H, m, H-4), 7.10–7.04 (1H, m, H-7), 7.02–7.00 (1H, m, H-8), 4.68–4.61 (1H, m, H-1), 3.86–3.80 (1H, m, H-13), 3.62 (3H, br s, OMe), 3.24–3.17 (1H, m, H-2a), 3.11–3.02 (1H, m, H-2b), 3.01–2.92 (2H, m, H₂-16), 1.62–1.49 (2H, m, H₂-15), 1.36–1.25 (1H, m, H-14a), 1.25–1.12 (1H, m, 14b); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 171.8 (C-10), 168.4 (C-12), 156.8 (C-18), 136.1 (C-5a), 126.9 (C-9a), 124.0 (C-4), 121.1 (C-7), 118.5 (C-8), 117.9 (C-9), 111.5 (C-6), 109.0 (C-3), 53.0 (C-1), 52.1 (OMe), 51.6 (C-13), 40.0 (C-16), 28.3 (C-15), 27.4 (C-2), 23.7 (C-14); (+)-HRESIMS [M+H]⁺ m/z 375.2139 (calcd for C₁₈H₂₇N₆O₃, 375.2139).

3.1.11. Methyl L-arginyl-D-tryptophanate bis(2,2,2-trifluoroacetate) (4d).

369 Following general procedure B, Boc-protected dipeptide **3d** (35 mg, 0.068 mmol)
370 was reacted with TFA in CH₂Cl₂ to afford the di-TFA salt of dipeptide **4d** as a pale-yellow
371 oil/gum (23 mg, 56%). [α]^{19D} +27 (*c* 0.10, MeOH); *R*_f = 0.35 (MeOH); IR (ATR) ν_{\max} 3347,
372 3195, 3080, 2948, 2871, 1666, 1624, 1590, 1439, 1200, 1184, 1134 cm⁻¹; ¹H NMR (400 MHz,
373 DMSO-*d*₆) δ 10.91–10.87 (1H, m, NH-5), 8.95 (1H, d, *J* = 7.8 Hz, NH-11), 7.86–7.23 (1H, m,
374 NH-17), 7.50 (1H, d, *J* = 7.8 Hz, H-9), 7.35 (1H, d, *J* = 7.8 Hz, H-6), 7.18–7.13 (1H, m, H-4),
375 7.11–7.04 (1H, m, H-7), 7.03–6.97 (1H, m, H-8), 4.64 (1H, dt, *J* = 9.2, 6.7 Hz, H-1), 3.86–3.77
376 (1H, m, H-13), 3.62 (3H, br s, OMe), 3.25–3.17 (1H, m, H-2a), 3.11–3.02 (1H, m, H-2b),
377 3.02–2.91 (2H, m, H₂-16), 1.65–1.49 (2H, m, H₂-15), 1.37–1.25 (1H, m, H-14a), 1.25–1.14
378 (1H, m, H-14b); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 171.8 (C-10), 168.4 (C-12), 156.9 (C-18),
379 136.1 (C-5a), 126.9 (C-9a), 124.0 (C-4), 121.1 (C-7), 118.5 (C-8), 117.9 (C-9), 111.5 (C-6),
380 108.9 (C-3), 53.0 (C-1), 52.0 (OMe), 51.7 (C-13), 40.0 (C-16), 28.3 (C-15), 27.4 (C-2), 23.7
381 (C-14); (+)-HRESIMS [M+H]⁺ *m/z* 375.2134 (calcd for C₁₈H₂₇N₆O₃, 375.2139).

3.1.12. Cyclo(L-Trp-L-Arg) 2,2,2-trifluoroacetate (**5a**).

384 Following general procedure C, dipeptide **4a** (113 mg, 0.189 mmol) was reacted with
385 NH₄OH (0.13 mL) in MeOH (0.76 mL) to afford the TFA salt of cyclo(L-Trp-L-Arg) (**5a**) as
386 a pale-yellow oil/gum (47 mg, 55%). [α]^{24D} -10.5 (*c* 0.105, MeOH); ECD (*c* 0.00035, MeOH)
387 λ ($\Delta\epsilon$) 194 (0), 210 (-17.4), 223 (0), 231 (+10.2); *R*_f = 0.60 (MeOH); IR (ATR) ν_{\max} 3363, 3233,
388 2969, 1659, 1648, 1457, 1137, 1106, 748 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.88–10.84
389 (1H, m, NH-17), 8.09 (1H, d, *J* = 2.0 Hz, NH-4), 8.01–7.97 (1H, m, NH-1), 7.57 (1H, d, *J* = 7.9
390 Hz, H-21), 7.33 (1H, d, *J* = 7.9 Hz, H-18), 7.27–7.19 (1H, m, NH-10), 7.08–7.04 (1H, m,
391 H-16), 7.05–7.00 (1H, m, H-19), 7.00–6.91 (1H, m, H-20), 4.14–4.09 (1H, br m, H-3),
392 3.59–3.53 (1H, br m, H-6), 3.23 (1H, dd, *J* = 14.5, 4.5 Hz, H-14a), 3.04 (1H, dd, *J* = 14.5, 4.5
393 Hz, H-14b), 2.72–2.64 (2H, m, H₂-9), 1.08–0.95 (1H, m, H-7a), 0.95–0.78 (2H, m, H₂-8),
394 0.67–0.55 (1H, m, H-7b); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 167.2 (C-2), 166.9 (C-5), 156.7
395 (C-11), 135.9 (C-17a), 127.8 (C-21a), 124.6 (C-16), 120.8 (C-19), 119.0 (C-21), 118.4 (C-20),
396 111.2 (C-18), 108.6 (C-15), 55.5 (C-3), 53.4 (C-6), 40.1 (C-9), 30.6 (C-7), 29.0 (C-14), 23.4
397 (C-8); (+)-HRESIMS [M+H]⁺ *m/z* 343.1874 (calcd for C₁₇H₂₃N₆O₂, 343.1877).

398 ¹H NMR (400 MHz, CD₃OD) δ 7.63 (1H, d, *J* = 8.0 Hz, H-21), 7.35 (1H, d, *J* = 8.0 Hz,
399 H-18), 7.12–7.07 (1H, m, H-19), 7.08 (1H, br s, H-16), 7.04–6.98 (1H, m, H-20), 4.31 (1H,
400 ddd, *J* = 4.6, 4.0, 1.2 Hz, H-3), 3.68 (1H, ddd, *J* = 7.4, 6.5, 1.2 Hz, H-6), 3.49 (1H, dd, *J* = 14.6,
401 3.7 Hz, H-14a), 3.14 (1H, dd, *J* = 14.6, 4.6 Hz, H-14b), 2.62 (2H, t, *J* = 7.1 Hz, H₂-9), 0.93–0.80
402 (2H, m, H-7a, H-8a), 0.77–0.65 (1H, m, H-8b), 0.56–0.45 (1H, m, H-7b); ¹³C NMR (100
403 MHz, CD₃OD) δ 169.9 (C-2), 169.5 (C-5), 158.5 (C-11), 137.8 (C-17a), 129.4 (C-21a), 126.1
404 (C-16), 122.5 (C-19), 120.3 (C-20), 120.2 (C-21), 112.2 (C-18), 109.6 (C-15), 57.5 (C-3), 55.2
405 (C-6), 41.7 (C-9), 32.1 (C-7), 30.5 (C-14), 24.5 (C-8).

3.1.13. Cyclo(D-Trp-D-Arg) 2,2,2-trifluoroacetate (**5b**).

408 Following general procedure C, dipeptide **4b** (27 mg, 0.045 mmol) was reacted with
409 NH₄OH (0.03 mL) in MeOH (0.18 mL) to afford the TFA salt of cyclo(D-trp-D-Arg) (**5b**) as
410 a pale-yellow oil/gum (15 mg, 71%). [α]^{24D} +10.7 (*c* 0.103, MeOH); ECD (*c* 0.00037, MeOH)
411 λ ($\Delta\epsilon$) 195 (0), 213 (+18.7), 223 (0), 230 (-9.83); *R*_f = 0.60 (MeOH); IR (ATR) ν_{\max} 3350, 3216,
412 2979, 1659, 1654, 1457, 1201, 1137 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.87–10.83 (1H,
413 m, NH-17), 8.09 (1H, d, *J* = 2.2 Hz, NH-4), 8.00 (1H, d, *J* = 2.2 Hz, NH-1), 7.57 (1H, d, *J* = 8.0
414 Hz, H-21), 7.32 (1H, d, *J* = 8.0 Hz, H-18), 7.25–7.12 (1H, m, NH-10), 7.07–7.05 (1H, m,
415 H-16), 7.06–7.01 (1H, m, H-19), 6.97–6.91 (1H, m, H-20), 4.14–4.09 (1H, br m, H-3),
416 3.59–3.53 (1H, br m, H-6), 3.23 (1H, dd, *J* = 14.6, 4.4 Hz, H-14a), 3.04 (1H, dd, *J* = 14.6, 4.6
417 Hz, H-14b), 2.74–2.64 (2H, m, H₂-9), 1.08–0.96 (1H, m, H-7a), 0.96–0.79 (2H, m, H₂-8),
418 0.66–0.54 (1H, m, H-7b); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 167.2 (C-2), 166.9 (C-5), 156.6
419 (C-11), 135.9 (C-17a), 127.8 (C-21a), 124.6 (C-16), 120.8 (C-19), 119.0 (C-21), 118.4 (C-20),
420 111.1 (C-18), 108.7 (C-15), 55.4 (C-3), 53.4 (C-6), 40.1 (C-9), 30.6 (C-7), 29.0 (C-14), 23.4
421 (C-8); (+)-HRESIMS [M+H]⁺ *m/z* 343.1867 (calcd for C₁₇H₂₃N₆O₂, 343.1877).

¹H NMR (400 MHz, CD₃OD) δ 7.63 (1H, d, *J* = 8.0 Hz, H-21), 7.35 (1H, d, *J* = 8.0 Hz, H-18), 7.09 (1H, ddd, *J* = 8.2, 8.0, 1.0 Hz, H-19), 7.08 (1H, br s, H-16), 7.01 (1H, ddd, *J* = 8.2, 8.0, 1.0 Hz, H-20), 4.31 (1H, ddd, *J* = 5.0, 4.0, 1.0 Hz, H-3), 3.68 (1H, ddd, *J* = 7.5, 6.2, 1.2 Hz, H-6), 3.48 (1H, dd, *J* = 14.6, 3.8 Hz, H-14a), 3.14 (1H, dd, *J* = 14.6, 4.6 Hz, H-14b), 2.62 (2H, t, *J* = 7.1 Hz, H₂-9), 0.94–0.79 (2H, m, H-7a, H-8a), 0.77–0.64 (1H, m, H-8b), 0.54–0.43 (1H, m, H-7b); ¹³C NMR (100 MHz, CD₃OD) δ 169.9 (C-2), 169.5 (C-5), 158.4 (C-11), 137.8 (C-17a), 129.4 (C-21a), 126.0 (C-16), 122.5 (C-19), 120.2 (C-20, C-21), 112.2 (C-18), 109.6 (C-15), 57.5 (C-3), 55.2 (C-6), 41.7 (C-9), 32.0 (C-7), 30.4 (C-14), 24.5 (C-8).

3.1.14. Cyclo(L-Trp-D-Arg) 2,2,2-trifluoroacetate (**5c**).

Following general procedure C, dipeptide **4c** (118.1 mg, 0.196 mmol) was reacted with NH₄OH (0.13 mL) in MeOH (0.78 mL) to afford the TFA salt of cyclo(L-Trp-D-Arg) (**5c**) as a pale-yellow oil/gum (48 mg, 54%). [α]^{21D} +26.0 (*c* 0.131, MeOH); ECD (*c* 0.00035, MeOH) λ ($\Delta\epsilon$) 204 (0), 216 (-10.6), 227 (0), 235 (+2.95); *R*_f = 0.49 (MeOH); IR (ATR) ν_{\max} 3356, 3215, 2961, 2903, 1662, 1458, 1202, 1138 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.91 (1H, d, *J* = 2.0 Hz, NH-17), 8.10 (1H, d, *J* = 2.2 Hz, NH-4), 7.91–7.90 (1H, m, NH-1), 7.57 (1H, d, *J* = 7.9 Hz, H-21), 7.47 (1H, t, *J* = 5.2 Hz, NH-10), 7.32 (1H, d, *J* = 7.9 Hz, H-18), 7.07 (1H, d, *J* = 2.0 Hz, H-16), 7.04 (1H, ddd, *J* = 8.4, 7.9, 1.0 Hz, H-19), 6.95 (1H, ddd, *J* = 8.4, 7.9, 1.0 Hz, H-20), 4.10–4.05 (1H, br m, H-3), 3.29–3.22 (1H, dd, *J* = 14.5, 4.5 Hz, H-14a), 3.10–3.01 (1H, m, H-14b), 3.08–3.03 (1H, m, H-6), 3.02–3.00 (2H, m, H₂-9), 1.61–1.50 (1H, m, H-7a), 1.50–1.42 (1H, m, H-7b), 1.42–1.30 (2H, m, H₂-8); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 168.2 (C-2), 167.5 (C-5), 156.7 (C-11), 135.9 (C-17a), 127.6 (C-21a), 124.6 (C-16), 120.9 (C-19), 118.8 (C-21), 118.4 (C-20), 111.2 (C-18), 108.4 (C-15), 55.4 (C-3), 52.9 (C-6), 40.4 (C-9), 29.1 (C-7), 28.9 (C-14), 23.5 (C-8); (+)-HRESIMS [M+H]⁺ *m/z* 343.1874 (calcd for C₁₇H₂₃N₆O₂, 343.1877).

¹H NMR (400 MHz, CD₃OD) δ 7.60 (1H, d, *J* = 8.0 Hz, H-21), 7.33 (1H, d, *J* = 8.0 Hz, H-18), 7.11–7.05 (1H, m, H-19), 7.06 (1H, br s, H-16), 7.00 (1H, ddd, *J* = 8.5, 8.0, 1.0 Hz, H-20), 4.22 (1H, t, *J* = 4.0 Hz, H-3), 3.46 (1H, dd, *J* = 14.6, 4.0 Hz, H-14a), 3.15 (1H, dd, *J* = 14.6, 4.4 Hz, H-14b), 3.04 (2H, t, *J* = 6.8 Hz, H₂-9), 2.77 (1H, t, *J* = 4.0 Hz, H-6), 1.73–1.62 (1H, m, H-7a), 1.54–1.32 (3H, m, H-7b, H₂-8); ¹³C NMR (100 MHz, CD₃OD) δ 171.4 (C-2), 170.3 (C-5), 158.6 (C-11), 137.9 (C-17a), 128.8 (C-21a), 126.1 (C-16), 122.6 (C-19), 120.2 (C-20), 119.8 (C-21), 112.2 (C-18), 109.0 (C-15), 57.7 (C-3), 54.3 (C-6), 42.0 (C-9), 31.1 (C-14), 29.6 (C-7), 24.3 (C-8).

3.1.15. Cyclo(D-Trp-L-Arg) 2,2,2-trifluoroacetate (**5d**).

Following general procedure C, dipeptide **4d** (52 mg, 0.086 mmol) was reacted with NH₄OH (0.057 mL) in MeOH (0.344 mL) to afford the TFA salt of cyclo(D-Trp-L-Arg) (**5d**) as a pale-yellow gum (18 mg, 47%). [α]^{19D} -26.4 (*c* 0.421, MeOH); ECD (*c* 0.00035, MeOH) λ ($\Delta\epsilon$) 204 (0), 216 (+11.8), 227 (0), 234 (-1.75); *R*_f = 0.49 (MeOH); IR (ATR) ν_{\max} 3342, 3214, 2964, 1662, 1651, 1456, 1431, 1201, 1135 cm⁻¹; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.93 (1H, d, *J* = 2.0 Hz, NH-17), 8.11–8.09 (1H, m, NH-4), 7.92–7.90 (1H, m, NH-1), 7.63 (1H, t, *J* = 5.5 Hz, NH-10), 7.57 (1H, d, *J* = 8.1 Hz, H-21), 7.32 (1H, d, *J* = 8.1 Hz, H-18), 7.07 (1H, d, *J* = 2.0 Hz, H-16), 7.04 (1H, ddd, *J* = 8.1, 7.5, 1.0 Hz, H-19), 6.94 (1H, ddd, *J* = 8.1, 7.5, 1.0 Hz, H-20), 4.10–4.04 (1H, br m, H-3), 3.29–3.21 (1H, dd, *J* = 14.5, 4.4 Hz, H-14a), 3.09–3.03 (1H, m, H-6), 3.08–3.01 (1H, m, H-14b), 3.02–3.00 (2H, m, H₂-9), 1.61–1.45 (2H, m, H₂-7), 1.43–1.31 (2H, m, H₂-8); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 168.2 (C-2), 167.5 (C-5), 156.8 (C-11), 135.9 (C-17a), 127.6 (C-21a), 124.6 (C-16), 120.9 (C-19), 118.8 (C-21), 118.4 (C-20), 111.2 (C-18), 108.4 (C-15), 55.4 (C-3), 52.9 (C-6), 40.5 (C-9), 29.1 (C-7), 28.9 (C-14), 23.5 (C-8); (+)-HRESIMS [M+H]⁺ *m/z* 343.1870 (calcd for C₁₇H₂₃N₆O₂, 343.1877).

¹H NMR (400 MHz, CD₃OD) δ 7.60 (1H, d, *J* = 8.0 Hz, H-21), 7.33 (1H, d, *J* = 8.0 Hz, H-18), 7.11–7.05 (1H, m, H-19), 7.06 (1H, br s, H-16), 7.03–6.98 (1H, m, H-20), 4.23 (1H, t, *J* = 4.1 Hz, H-3), 3.46 (1H, dd, *J* = 14.6, 4.0 Hz, H-14a), 3.15 (1H, dd, *J* = 14.6, 4.5 Hz, H-14b), 3.04 (2H, t, *J* = 6.7 Hz, H-9), 2.78 (1H, t, *J* = 3.9 Hz, H-6), 1.73–1.61 (1H, m, H-7a), 1.54–1.33 (3H, m, H-7b, H₂-8); ¹³C NMR (100 MHz, CD₃OD) δ 171.4 (C-2), 170.3 (C-5), 158.6 (C-11),

137.9 (C-17a), 128.8 (C-21a), 126.1 (C-16), 122.6 (C-19), 120.2 (C-20), 119.8 (C-21), 112.2 (C-18), 109.0 (C-15), 57.7 (C-3), 54.3 (C-6), 42.0 (C-9), 31.1 (C-14), 29.6 (C-7), 24.3 (C-8).

3.2. Antimicrobial Assays

The susceptibility of bacterial strains *S. aureus* (ATCC 25923 or 29213), and *P. aeruginosa* (ATCC 27853 or PAO1) to antibiotics and compounds was determined in microplates using the standard broth dilution method in accordance with the recommendations of the Comité de l'AntibioGramme de la Société Française de Microbiologie (CA-SFM). Briefly, the minimal inhibitory concentrations (MICs) were determined with an inoculum of 10^5 CFU in 200 μ L of Mueller-Hinton broth (MHB) containing two-fold serial dilutions of each drug. The MIC was defined as the lowest concentration of drug that completely inhibited visible growth after incubation for 18 h at 37 °C. To determine all MICs, the measurements were independently repeated in triplicate.

Additional antimicrobial evaluation against *S. aureus* (MRSA) (ATCC 43300), *E. coli* (ATCC 25922), *K. pneumoniae* (ATCC 700603), *A. baumannii* (ATCC 19606), *C. albicans* (ATCC 90028), and *C. neoformans* (ATCC 208821) was undertaken at the Community for Open Antimicrobial Drug Discovery at The University of Queensland (Australia) according to their standard protocols [3]. For antimicrobial assays, the tested strains were cultured in either Luria broth (LB) (In Vitro Technologies, USB75852), nutrient broth (NB) (Becton Dickson, 234000), or MHB at 37 °C overnight. A sample of culture was then diluted 40-fold in fresh MHB and incubated at 37 °C for 1.5–2 h. The compounds were serially diluted 2-fold across the wells of 96-well plates (Corning 3641, nonbinding surface), with compound concentrations ranging from 0.015 to 64 μ g/mL, plated in duplicate. The resultant mid log phase cultures were diluted to the final concentration of 1×10^6 CFU/mL; then, 50 μ L was added to each well of the compound containing plates giving a final compound concentration range of 0.008 to 32 μ g/mL and a cell density of 5×10^5 CFU/mL. All plates were then covered and incubated at 37 °C for 18 h. Resazurin was added at 0.001% final concentration to each well and incubated for 2 h before MICs were read by eye.

For the antifungal assay, fungi strains were cultured for 3 days on YPD agar at 30 °C. A yeast suspension of 1×10^6 to 5×10^6 CFU/mL was prepared from five colonies. These stock suspensions were diluted with yeast nitrogen base (YNB) (Becton Dickinson, 233520) broth to a final concentration of 2.5×10^3 CFU/mL. The compounds were serially diluted 2-fold across the wells of 96-well plates (Corning 3641, nonbinding surface), with compound concentrations ranging from 0.015 to 64 μ g/mL and final volumes of 50 μ L, plated in duplicate. Then, 50 μ L of the fungi suspension that was previously prepared in YNB broth to the final concentration of 2.5×10^3 CFU/mL was added to each well of the compound-containing plates, giving a final compound concentration range of 0.008 to 32 μ g/mL. Plates were covered and incubated at 35 °C for 36 h without shaking. *C. albicans* MICs were determined by measuring the absorbance at OD₅₃₀. For *C. neoformans*, resazurin was added at 0.006% final concentration to each well and incubated for a further 3 h before MICs were determined by measuring the absorbance at OD_{570–600}.

Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative and Gram-positive bacteria, respectively. Fluconazole was used as a positive fungal inhibitor standard for *C. albicans* and *C. neoformans*. The antibiotics were provided in 4 concentrations, with 2 above and 2 below its MIC value, and plated into the first 8 wells of column 23 of the 384-well NBS plates. The quality control (QC) of the assays was determined by the antimicrobial controls and the Z'-factor (using positive and negative controls). Each plate was deemed to fulfil the quality criteria (pass QC), if the Z'-factor was above 0.4, and the antimicrobial standards showed full range of activity, with full growth inhibition at their highest concentration, and no growth inhibition at their lowest concentration.

3.3. Determination of the MICs of antibiotics in the presence of synergizing compounds

Briefly, restoring enhancer concentrations were determined with an inoculum of 5×10^5 CFU in 200 μ L of MHB containing two-fold serial dilutions of each derivative in the presence of either doxycycline or ampicillin at 2 μ g/mL. The lowest concentration of the synthetic material that completely inhibited visible growth after incubation for 18 h at 37 °C was determined. These measurements were independently repeated in triplicate.

3.4. Cytotoxicity Assays

HEK293 cells (ATCC CRL-1573) were counted manually in a Neubauer hemocytometer and plated at a density of 5,000 cells/well into each well of the 384-well plates containing the 25x (2 μ L) concentrated compounds. The medium used was Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were incubated together with the compounds for 20 h at 37 °C, 5% CO₂. To measure cytotoxicity, 5 μ L (equals 100 μ M final) of resazurin was added to each well after incubation and incubated for further 3 h at 37 °C with 5% CO₂. After final incubation fluorescence intensity was measured as Fex 560/10 nm, em 590/10 nm (F_{560/590}) using a Tecan M1000 Pro monochromator plate reader. CC₅₀ values (concentration at 50% cytotoxicity) were calculated by normalizing the fluorescence readout, with 74 μ g/mL tamoxifen as negative control (0%) and normal cell growth as positive control (100%). The concentration-dependent percentage cytotoxicity was fitted to a dose response function (using Pipeline Pilot) and CC₅₀ values determined.

3.5. Hemolytic Assays

Human whole blood (ARCBS 5400 00150) was washed three times with 3 volumes of 0.9% NaCl and then resuspended in same to a concentration of 0.5×10^8 cells/mL, as determined by manual cell count in a Neubauer hemocytometer. The washed cells were then added to the 384-well compound-containing plates for a final volume of 50 μ L. After a 10 min shake on a plate shaker the plates were then incubated for 1 h at 37 °C. After incubation, the plates were centrifuged at 1,000g for 10 min to pellet cells and debris, 25 μ L of the supernatant was then transferred to a polystyrene 384-well assay plate. Hemolysis was determined by measuring the supernatant absorbance at 405 nm (OD₄₀₅). The absorbance was measured using a Tecan M1000 Pro monochromator plate reader. HC₁₀ and HC₅₀ (concentration at 10% and 50% hemolysis, respectively) were calculated by curve fitting the inhibition values *vs.* log (concentration) using a sigmoidal dose-response function with variable fitting values for top, bottom and slope.

4. Conclusions

In summary, we have synthesized the four diastereomers of diketopiperazine cyclo(Trp-Arg) and characterized them extensively using NMR, ESIMS and chiroptical methods. Our data, while being in close agreement with previously reported spectroscopic data [9,12], raises uncertainty regarding the structure of cyclo(L-Trp-L-Arg) CDP2 reported from the bacterium *Achromobacter* sp. [8]. Based upon available data, we are not able to assign a structure or relative configuration to natural product CDP3 **2** at this time. Antimicrobial and antibiotic enhancing activities attributed to the natural products [8] were not observed for the synthesized diketopiperazines leading us to conclude that these specific cyclic dipeptides do not represent viable templates for the development of new treatments for microbial infections. This study also illustrates the key role total synthesis continues to play in the establishment/confirmation of absolute configuration of natural products.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, Figure S1: ¹H and ¹³C NMR data (DMSO-*d*₆) for cyclo(L-Trp-L-Arg) (**5a**); Figure S2: ¹H and ¹³C NMR data (CD₃OD) for cyclo(L-Trp-L-Arg) (**5a**); Figure S3: ¹H and ¹³C NMR data (DMSO-*d*₆) for cyclo(D-Trp-D-Arg) (**5b**); Figure S4: ¹H and ¹³C NMR data (CD₃OD) for cyclo(D-Trp-D-Arg) (**5b**); Figure S5: ¹H and ¹³C NMR data (DMSO-*d*₆) for cyclo(L-Trp-D-Arg) (**5c**);

Figure S6: ^1H and ^{13}C NMR data (CD_3OD) for cyclo(L-Trp-D-Arg) (**5c**); Figure S7: ^1H and ^{13}C NMR data ($\text{DMSO-}d_6$) for cyclo(D-Trp-L-Arg) (**5d**); Figure S8: ^1H and ^{13}C NMR data (CD_3OD) for cyclo(D-Trp-L-Arg) (**5d**); Table S1: Comparison of ^1H NMR chemical shifts observed for **5a** and **5c** with corresponding shifts reported by Li *et al.* and calculated values of mean absolute error (MAE); Table S2: Comparison of ^{13}C NMR chemical shifts (CD_3OD) observed for **5a** and **5c** with corresponding shifts reported by Li *et al.* and calculated values of mean absolute error (MAE); Table S3: Comparison of ^1H NMR chemical shifts reported for CDP 2 (**1**) with corresponding shifts observed for **5a** (cyclo(L-Trp-L-Arg) in either $\text{DMSO-}d_6$ or CD_3OD (with exchangeables in $\text{DMSO-}d_6$) and calculated values of mean absolute error (MAE); Table S4: Comparison of ^1H NMR chemical shifts reported for CDP 3 (**2**) with corresponding shifts observed for **5a** (cyclo(L-Trp-L-Arg) in either $\text{DMSO-}d_6$ or CD_3OD (with exchangeables in $\text{DMSO-}d_6$) and calculated values of mean absolute error (MAE); Table S5: Comparison of ^{13}C NMR chemical shifts reported for CDP 2 (**1**) with corresponding shifts observed for **5a** (cyclo(L-Trp-L-Arg) in either $\text{DMSO-}d_6$ or CD_3OD and calculated values of mean absolute error (MAE); Table S6: Comparison of ^{13}C NMR chemical shifts reported for CDP 3 (**2**) with corresponding shifts observed for **5a** (cyclo(L-Trp-L-Arg) in either $\text{DMSO-}d_6$ or CD_3OD and calculated values of mean absolute error (MAE).

Author Contributions: Conceptualization, B.R.C.; methodology, D.C., D.J.P., H.D.; formal analysis, B.R.C.; investigation, B.R.C., D.C., M.M.C., D.J.P., H.D., M-L.B-K, J.M.B.; resources, B.R.C., J.M.B.; data curation, B.R.C.; writing—original draft preparation, B.R.C., D.C., M.M.C.; writing—review and editing, B.R.C., D.C., M.M.C., M-L.B-K, J.M.B.; supervision, B.R.C., M.M.C., J.M.B.; project administration, B.R.C., M.M.C.; funding acquisition, B.R.C., M.M.C., M-L.B-K, J.M.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Catalyst: Seeding Dumont d'Urville NZ-France Science & Technology Support Programme (19-UOA-057-DDU) provided by the New Zealand Ministry of Business, Innovation and Employment and administered by the Royal Society Te Apārangi.

Data Availability Statement: Data are contained within the article or Supplementary Material.

Acknowledgments: We thank Professor Kathrin Hopmann and Dr Johan Isaksson (UiT – The Arctic University of Norway) for helpful discussions and providing digital copies of their NMR data as reported in reference Li *et al.* [12]. We also thank Dr. Michael Schmitz and Dr Mansa Nair for their assistance with NMR and mass spectrometric data. Some of the antimicrobial screening was performed by CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and The University of Queensland (Australia).

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the final compounds **5a-d** are available from the authors.

References

1. Payne, D.J.; Gwynn, M.N.; Holmes, D.J.; Pompliano, D.L. Drugs for Bad Bugs: Confronting the Challenges of Antibacterial Discovery. *Nat. Rev. Drug Discov.* **2007**, *6*, 29–40, doi:10.1038/nrd2201.
2. Silver, L.L. Challenges of Antibacterial Discovery. *Clin. Microbiol. Rev.* **2011**, *24*, 71–109, doi:10.1128/CMR.00030-10.
3. Blaskovich, M.A.T.; Zuegg, J.; Elliott, A.G.; Cooper, M.A. Helping Chemists Discover New Antibiotics. *ACS Infect. Dis.* **2015**, *1*, 285–287, doi:10.1021/acsinfecdis.5b00044.
4. Miethke, M.; Pieroni, M.; Weber, T.; Brønstrup, M.; Hammann, P.; Halby, L.; Arimondo, P.B.; Glaser, P.; Aigle, B.; Bode, H.B.; et al. Towards the Sustainable Discovery and Development of New Antibiotics. *Nat. Rev. Chem.* **2021**, *5*, 726–749, doi:10.1038/s41570-021-00313-1.
5. Jackson, N.; Czaplowski, L.; Piddock, L.J.V. Discovery and Development of New Antibacterial Drugs: Learning from Experience? *J. Antimicrob. Chemother.* **2018**, *73*, 1452–1459, doi:10.1093/jac/dky019.
6. Cadelis, M.M.; Li, S.A.; Bourguet-Kondracki, M.; Blanchet, M.; Douafer, H.; Brunel, J.M.; Copp, B.R. Spermine Derivatives of Indole-3-carboxylic Acid, Indole-3-acetic Acid and Indole-3-acrylic Acid as Gram-Negative Antibiotic Adjuvants. *ChemMedChem* **2021**, *16*, 513–523, doi:10.1002/cmdc.202000359.

- 626 7. Li, S.A.; Cadelis, M.M.; Deed, R.C.; Douafer, H.; Bourguet-Kondracki, M.-L.; Michel Brunel, J.; Copp, B.R. Valorisation of the
627 Diterpene Podocarpic Acid – Antibiotic and Antibiotic Enhancing Activities of Polyamine Conjugates. *Bioorg. Med. Chem.* **2022**,
628 *64*, 116762, doi:10.1016/j.bmc.2022.116762.
- 629 8. Deepa, I.; Kumar, S.N.; Sreerag, R.S.; Nath, V.S.; Mohandas, C. Purification and Synergistic Antibacterial Activity of Arginine
630 Derived Cyclic Dipeptides, from *Achromobacter* sp. Associated with a Rhabditid Entomopathogenic Nematode against Major
631 Clinically Relevant Biofilm Forming Wound Bacteria. *Front. Microbiol.* **2015**, *6*, doi:10.3389/fmicb.2015.00876.
- 632 9. Li, X.; Hopmann, K.H.; Hudecová, J.; Isaksson, J.; Novotná, J.; Stensen, W.; Andrushchenko, V.; Urbanová, M.; Svendsen, J.-S.;
633 Bouř, P.; et al. Determination of Absolute Configuration and Conformation of a Cyclic Dipeptide by NMR and Chiral Spec-
634 troscopic Methods. *J. Phys. Chem. A* **2013**, *117*, 1721–1736, doi:10.1021/jp311151h.
- 635 10. Johnson, A.-L.; Bergman, J.; Sjögren, M.; Bohlin, L. Synthesis of Baretin. *Tetrahedron* **2004**, *60*, 961–965,
636 doi:10.1016/j.tet.2003.11.031.
- 637 11. Kieffer, M.E.; Chuang, K.V.; Reisman, S.E. Copper-Catalyzed Diastereoselective Arylation of Tryptophan Deriva-
638 tives: Total Synthesis of (+)-Naseseazines A and B. *J. Am. Chem. Soc.* **2013**, *135*, 5557–5560, doi:10.1021/ja4023557
- 639 12. Sasaki, Y.; Akutsu, Y.; Matsui, M.; Suzuki, K.; Sakurada, S.; Sato, T.; Kisara, K. Studies on Analgesic Oligopeptides. II. Struc-
640 ture-Activity Relationship among Thirty Analogs of a Cyclic Dipeptide, Cyclo (-Tyr-Arg-). *Chem. Pharm. Bull. (Tokyo)* **1982**, *30*,
641 4435–4443, doi:10.1248/cpb.30.4435.
- 642 13. Ref 12 also reported the melting point of cyclo(L-Trp-L-Arg) as mp 129–134 °C, which is considerably different to those re-
643 ported in Ref 8 for **1** (265.1–267.34 °C) and **2** (262.23–265.58 °C).
644